Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OT-A201 monotherapy and combinations in advanced cancers
NCT05828459Phase 1Recruiting
- Sponsor
- Onward Therapeutics
- Start
- Jul 2023
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of OT-A201 in hematologic malignancy and solid tumor (5 arms), sponsored by Onward Therapeutics. Primary endpoints: Maximum tolerated dose(s) (MTD) and recommended dose(s) of OT-A201 at 28 days and Safety profile of OT-A201 at 6 months. Started Jul 2023; status: recruiting.
02
Drugs
OT-A201
03
Conditions
hematologic malignancysolid tumor
Beyond the preview
Go deeper on NCT05828459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828459.